Source comparison
MOTS-c Dose Response Research: Comparison Across Administration Routes
Subcutaneous Injection 5–15mg, 2–3× weekly 100% (reference standard) 30–45 minutes Most studied route; predictable pharmacokinetics; suitable for clinical trials Requires injection training; local site reactions in 15–20% of users Gold standard for research ap
This comparison does not assign a generated winner or score.
- Subcutaneous Injection
- 5–15mg, 2–3× weekly
- 100% (reference standard)
- 30–45 minutes
- Most studied route; predictable pharmacokinetics; suitable for clinical trials
- Requires injection training; local site reactions in 15–20% of users
- Gold standard for research applications requiring precise dosing
- Intranasal Spray
- 10–20mg daily
- Approximately 60%
- 15–20 minutes
- Non-invasive; rapid CNS access; bypasses hepatic first-pass
- Higher per-dose cost; nasal irritation in some users; less published data
- Best for users prioritising convenience and willing to accept slightly higher dosing requirements
- Oral (Encapsulated)
- 50–100mg daily
- <5% (essentially negligible)
- Not applicable
- Easiest administration
- Degraded by gastric acid and proteases; no meaningful systemic absorption
- Not recommended. Insufficient bioavailability for therapeutic effect
- Transdermal (Experimental)
- 20–40mg daily
- 10–15% (highly variable)
- 60–90 minutes
- Sustained release profile
- Absorption depends on skin barrier integrity; limited research
- Insufficient evidence to recommend. Results too inconsistent across individuals
- The comparison table above reflects current mots-c dose response research as of early 2026. Subcutaneous administration remains the reference standard because it delivers the most consistent tissue exposure relative to administered dose. Intranasal routes are gaining traction for research applications where convenience matters and users can tolerate the 1.5–2× dose adjustment required to match subcutaneous efficacy. The MOTS-C Nasal Spray formulation we supply reflects this bioavailability difference. Dosing recommendations account for the reduced absorption to deliver equivalent tissue-level exposure.